About Us

Navira is start-up with academic roots. Formed in 2024, Navira develops AAV capsids, including proprietary patent-pending modular AAV technology.

Navira's nAAVigatorTM is a patent-pending platform technology to target AAVs to specific cell types.

Navira is currently funded via BBSRC ICURe Explore to conduct pre-company formation market exploration activities.

Are you interested in AAV-powered gene therapies? Share your thoughts! Take our survey and help us design better AAV capsids for future treatments:  Fill out the survey here!